B
Betsy J. Barnes
Researcher at Hofstra University
Publications - 10
Citations - 1331
Betsy J. Barnes is an academic researcher from Hofstra University. The author has contributed to research in topics: IRF5 & Immune system. The author has an hindex of 8, co-authored 10 publications receiving 744 citations. Previous affiliations of Betsy J. Barnes include The Feinstein Institute for Medical Research.
Papers
More filters
Journal ArticleDOI
Neutrophil extracellular traps in COVID-19.
Yu Zuo,Srilakshmi Yalavarthi,Hui Shi,Hui Shi,Kelsey Gockman,Melanie Zuo,Jacqueline A. Madison,Christopher N. Blair,Andrew G. Weber,Betsy J. Barnes,Betsy J. Barnes,Mikala Egeblad,Robert J. Woods,Yogendra Kanthi,Jason S. Knight +14 more
TL;DR: Sera from patients with COVID-19 have elevated levels of cell-free DNA, myeloperoxidase(MPO)-DNA, and citrullinated histone H3 (Cit-H3); the latter two are highly specific markers of NETs, which may contribute to cytokine release and respiratory failure.
Posted ContentDOI
Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19
Yu Zuo,Srilakshmi Yalavarthi,Hui Shi,Hui Shi,Kelsey Gockman,Melanie Zuo,Jacqueline A. Madison,Christopher N. Blair,Andrew G. Weber,Betsy J. Barnes,Betsy J. Barnes,Mikala Egeblad,Robert J. Woods,Yogendra Kanthi,Yogendra Kanthi,Jason S. Knight +15 more
TL;DR: Sera from patients with COVID-19 are reported to have elevated levels of cell-free DNA, myeloperoxidase(MPO)-DNA, and citrullinated histone H3 (Cit-H3); the latter two are highly specific markers of NETs, which may contribute to cytokine release and respiratory failure.
Journal ArticleDOI
Modulating Cytokine Production via Select Packaging and Secretion From Extracellular Vesicles.
TL;DR: This review will focus on these disease settings and summarize recent progress and mechanisms by which cytokines may be packaged within and modulated by EVs, as a therapeutic option for regulating innate and adaptive immunity.
Journal ArticleDOI
Inhibition of IRF5 hyperactivation protects from lupus onset and severity
Su Song,Saurav De,Victoria Nelson,Samin Chopra,Margaret LaPan,Kyle Kampta,Shan Sun,Mingzhu He,Cherrie D. Thompson,Dan Li,Tiffany Shih,Natalie Tan,Yousef Al-Abed,Eugenio Capitle,Cynthia Aranow,Meggan Mackay,William L. Clapp,Betsy J. Barnes +17 more
TL;DR: This study provides the first in vivo clinical support for treating SLE patients with an IRF5 inhibitor and developed novel inhibitors that are cell permeable, non-toxic and selectively bind to the inactive IRf5 monomer.
Journal ArticleDOI
IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE
Dan Li,Bharati Matta,Su Song,Victoria Nelson,Kirsten E. Diggins,Kim R. Simpfendorfer,Peter K. Gregersen,Peter S. Linsley,Betsy J. Barnes,Betsy J. Barnes +9 more
TL;DR: Data support that individuals carrying the IRF5-SLE risk haplotype are more susceptible to environmental/stochastic influences that trigger chronic immune activation, predisposing to the development of clinical SLE.